Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells

The objectives of this study were to determine the protein binding and lipoprotein distribution of G3139 and G3139 lipoplexes following incubation in human plasma, assess complement activation of, and the effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma on in vitro cellular upt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2002-07, Vol.241 (1), p.57-64
Hauptverfasser: Wasan, Ellen K, Waterhouse, Dawn, Sivak, Olena, Bally, Marcel B, Klasa, Richard J, Wasan, Kishor M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 64
container_issue 1
container_start_page 57
container_title International journal of pharmaceutics
container_volume 241
creator Wasan, Ellen K
Waterhouse, Dawn
Sivak, Olena
Bally, Marcel B
Klasa, Richard J
Wasan, Kishor M
description The objectives of this study were to determine the protein binding and lipoprotein distribution of G3139 and G3139 lipoplexes following incubation in human plasma, assess complement activation of, and the effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma on in vitro cellular uptake of G3139. Effect of concentration and time on incorporation of free and lipid associated (lipoplexes) [3H] Bcl-2 AO (25–600 ng/ml) into normolipidemic human plasma lipoproteins was determined by density gradient ultracentrifugation after incubation at 37 °C for 5, 30, 60 and 120 min. Protein binding in the lipoprotein deficient fractions (LPDP) was determined by equilibrium dialysis. Complement interaction was determined by ELISA after exposure of human plasma to AO+/− liposomes prepared in serial dilution. In vitro uptake of G3139 and G3139 lipoplexes into human melanoma cells was assessed qualitatively by fluorescence microscopy after 4-h exposure to G3139 (free or as lipoplexes) with or without pre-incubation of G3139 in normal human plasma. Analysis of Bcl-2 AO-lipoprotein interaction over time and concentration indicated no significant movement of the compound within the different lipoprotein and LPDP fractions. Majority of drug was recovered within LPDP fraction, and more than 85% of drug recovered within LPDP fraction was protein bound. No significant activation of complement was noted for either free AO or lipoplexes. Pre-incubation of free AO or AO-lipoplexes in human plasma resulted in a greater cellular uptake of AO-lipoplexes compared with plasma free controls. These findings suggest that the majority of [3H]Bcl-2 AO is plasma protein bound with little lipoprotein association and no significant movement between different lipoprotein and LPDP fractions. Plasma protein binding other than lipoprotein binding may be responsible for the difference in cellular uptake of free AO vs. cationic lipoplexes.
doi_str_mv 10.1016/S0378-5173(02)00131-X
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71856925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S037851730200131X</els_id><sourcerecordid>71856925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-9d29e0ffe42a8d23f4165d6cbd99d8736fe8bb76cb034739d3ff3f481097c64a3</originalsourceid><addsrcrecordid>eNqFkc2OFCEUhYnROO3oI2jYaGYSS_mpKoqV0Y6OJp1ooiazIxRcRrQKeoAyzsv4rNI_OktXJIfvcg_nIPSYkheU0P7lZ8LF0HRU8DPCzgmhnDaXd9CKDoI3vBX9XbT6h5ygBzl_J4T0jPL76IQyMvSC0RX6_WnSedZ4m2IBH_Dog_Xh6jme_Db-Fa3PJflxKT4GrIPFy7boH4Cjwy4B7KXKe9vonKPxuoDFb9abhtWr4jOEXOHJX0UL8ddNWMwEsXgLGZ9dcMrlOa5bvi2zDniGSYdYHRmYpvwQ3XN6yvDoeJ6ir-_eflm_bzYfLz6sX28awyUtjbRMAnEOWqYHy7hrad_Z3oxWSlsD6R0M4yiqQGo0XFruXIUGSqQwfav5KXp2eLd--XqBXNTs886BDhCXrAQdul6yroLdATQp5pzAqW3ys043ihK1K0bti1G71BVhal-MuqxzT44LlnEGezt1bKICT4-AzkZPLulgfL7luGBykG3lXh04qHH89JBUNh6CAesTmKJs9P-x8gdYtqzd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71856925</pqid></control><display><type>article</type><title>Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Wasan, Ellen K ; Waterhouse, Dawn ; Sivak, Olena ; Bally, Marcel B ; Klasa, Richard J ; Wasan, Kishor M</creator><creatorcontrib>Wasan, Ellen K ; Waterhouse, Dawn ; Sivak, Olena ; Bally, Marcel B ; Klasa, Richard J ; Wasan, Kishor M</creatorcontrib><description>The objectives of this study were to determine the protein binding and lipoprotein distribution of G3139 and G3139 lipoplexes following incubation in human plasma, assess complement activation of, and the effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma on in vitro cellular uptake of G3139. Effect of concentration and time on incorporation of free and lipid associated (lipoplexes) [3H] Bcl-2 AO (25–600 ng/ml) into normolipidemic human plasma lipoproteins was determined by density gradient ultracentrifugation after incubation at 37 °C for 5, 30, 60 and 120 min. Protein binding in the lipoprotein deficient fractions (LPDP) was determined by equilibrium dialysis. Complement interaction was determined by ELISA after exposure of human plasma to AO+/− liposomes prepared in serial dilution. In vitro uptake of G3139 and G3139 lipoplexes into human melanoma cells was assessed qualitatively by fluorescence microscopy after 4-h exposure to G3139 (free or as lipoplexes) with or without pre-incubation of G3139 in normal human plasma. Analysis of Bcl-2 AO-lipoprotein interaction over time and concentration indicated no significant movement of the compound within the different lipoprotein and LPDP fractions. Majority of drug was recovered within LPDP fraction, and more than 85% of drug recovered within LPDP fraction was protein bound. No significant activation of complement was noted for either free AO or lipoplexes. Pre-incubation of free AO or AO-lipoplexes in human plasma resulted in a greater cellular uptake of AO-lipoplexes compared with plasma free controls. These findings suggest that the majority of [3H]Bcl-2 AO is plasma protein bound with little lipoprotein association and no significant movement between different lipoprotein and LPDP fractions. Plasma protein binding other than lipoprotein binding may be responsible for the difference in cellular uptake of free AO vs. cationic lipoplexes.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/S0378-5173(02)00131-X</identifier><identifier>PMID: 12086721</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Antineoplastic agents ; Antisense therapy ; Bcl-2 ; Biological and medical sciences ; Blood Proteins - metabolism ; Chemotherapy ; Complement Activation - drug effects ; Genes, bcl-2 - genetics ; Genetic Therapy ; Human complement proteins ; Human melanoma cells ; Humans ; Lipids ; Lipoplexes ; Lipoproteins ; Lipoproteins - metabolism ; Medical sciences ; Melanoma - drug therapy ; Oligonucleotides, Antisense - pharmacology ; Pharmacology. Drug treatments ; Phosphorothioate oligodeoxynucleotides ; Plasma proteins ; Protein Binding ; Tumor Cells, Cultured</subject><ispartof>International journal of pharmaceutics, 2002-07, Vol.241 (1), p.57-64</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-9d29e0ffe42a8d23f4165d6cbd99d8736fe8bb76cb034739d3ff3f481097c64a3</citedby><cites>FETCH-LOGICAL-c391t-9d29e0ffe42a8d23f4165d6cbd99d8736fe8bb76cb034739d3ff3f481097c64a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0378-5173(02)00131-X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13729894$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12086721$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wasan, Ellen K</creatorcontrib><creatorcontrib>Waterhouse, Dawn</creatorcontrib><creatorcontrib>Sivak, Olena</creatorcontrib><creatorcontrib>Bally, Marcel B</creatorcontrib><creatorcontrib>Klasa, Richard J</creatorcontrib><creatorcontrib>Wasan, Kishor M</creatorcontrib><title>Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>The objectives of this study were to determine the protein binding and lipoprotein distribution of G3139 and G3139 lipoplexes following incubation in human plasma, assess complement activation of, and the effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma on in vitro cellular uptake of G3139. Effect of concentration and time on incorporation of free and lipid associated (lipoplexes) [3H] Bcl-2 AO (25–600 ng/ml) into normolipidemic human plasma lipoproteins was determined by density gradient ultracentrifugation after incubation at 37 °C for 5, 30, 60 and 120 min. Protein binding in the lipoprotein deficient fractions (LPDP) was determined by equilibrium dialysis. Complement interaction was determined by ELISA after exposure of human plasma to AO+/− liposomes prepared in serial dilution. In vitro uptake of G3139 and G3139 lipoplexes into human melanoma cells was assessed qualitatively by fluorescence microscopy after 4-h exposure to G3139 (free or as lipoplexes) with or without pre-incubation of G3139 in normal human plasma. Analysis of Bcl-2 AO-lipoprotein interaction over time and concentration indicated no significant movement of the compound within the different lipoprotein and LPDP fractions. Majority of drug was recovered within LPDP fraction, and more than 85% of drug recovered within LPDP fraction was protein bound. No significant activation of complement was noted for either free AO or lipoplexes. Pre-incubation of free AO or AO-lipoplexes in human plasma resulted in a greater cellular uptake of AO-lipoplexes compared with plasma free controls. These findings suggest that the majority of [3H]Bcl-2 AO is plasma protein bound with little lipoprotein association and no significant movement between different lipoprotein and LPDP fractions. Plasma protein binding other than lipoprotein binding may be responsible for the difference in cellular uptake of free AO vs. cationic lipoplexes.</description><subject>Antineoplastic agents</subject><subject>Antisense therapy</subject><subject>Bcl-2</subject><subject>Biological and medical sciences</subject><subject>Blood Proteins - metabolism</subject><subject>Chemotherapy</subject><subject>Complement Activation - drug effects</subject><subject>Genes, bcl-2 - genetics</subject><subject>Genetic Therapy</subject><subject>Human complement proteins</subject><subject>Human melanoma cells</subject><subject>Humans</subject><subject>Lipids</subject><subject>Lipoplexes</subject><subject>Lipoproteins</subject><subject>Lipoproteins - metabolism</subject><subject>Medical sciences</subject><subject>Melanoma - drug therapy</subject><subject>Oligonucleotides, Antisense - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphorothioate oligodeoxynucleotides</subject><subject>Plasma proteins</subject><subject>Protein Binding</subject><subject>Tumor Cells, Cultured</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2OFCEUhYnROO3oI2jYaGYSS_mpKoqV0Y6OJp1ooiazIxRcRrQKeoAyzsv4rNI_OktXJIfvcg_nIPSYkheU0P7lZ8LF0HRU8DPCzgmhnDaXd9CKDoI3vBX9XbT6h5ygBzl_J4T0jPL76IQyMvSC0RX6_WnSedZ4m2IBH_Dog_Xh6jme_Db-Fa3PJflxKT4GrIPFy7boH4Cjwy4B7KXKe9vonKPxuoDFb9abhtWr4jOEXOHJX0UL8ddNWMwEsXgLGZ9dcMrlOa5bvi2zDniGSYdYHRmYpvwQ3XN6yvDoeJ6ir-_eflm_bzYfLz6sX28awyUtjbRMAnEOWqYHy7hrad_Z3oxWSlsD6R0M4yiqQGo0XFruXIUGSqQwfav5KXp2eLd--XqBXNTs886BDhCXrAQdul6yroLdATQp5pzAqW3ys043ihK1K0bti1G71BVhal-MuqxzT44LlnEGezt1bKICT4-AzkZPLulgfL7luGBykG3lXh04qHH89JBUNh6CAesTmKJs9P-x8gdYtqzd</recordid><startdate>20020708</startdate><enddate>20020708</enddate><creator>Wasan, Ellen K</creator><creator>Waterhouse, Dawn</creator><creator>Sivak, Olena</creator><creator>Bally, Marcel B</creator><creator>Klasa, Richard J</creator><creator>Wasan, Kishor M</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020708</creationdate><title>Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells</title><author>Wasan, Ellen K ; Waterhouse, Dawn ; Sivak, Olena ; Bally, Marcel B ; Klasa, Richard J ; Wasan, Kishor M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-9d29e0ffe42a8d23f4165d6cbd99d8736fe8bb76cb034739d3ff3f481097c64a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antineoplastic agents</topic><topic>Antisense therapy</topic><topic>Bcl-2</topic><topic>Biological and medical sciences</topic><topic>Blood Proteins - metabolism</topic><topic>Chemotherapy</topic><topic>Complement Activation - drug effects</topic><topic>Genes, bcl-2 - genetics</topic><topic>Genetic Therapy</topic><topic>Human complement proteins</topic><topic>Human melanoma cells</topic><topic>Humans</topic><topic>Lipids</topic><topic>Lipoplexes</topic><topic>Lipoproteins</topic><topic>Lipoproteins - metabolism</topic><topic>Medical sciences</topic><topic>Melanoma - drug therapy</topic><topic>Oligonucleotides, Antisense - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphorothioate oligodeoxynucleotides</topic><topic>Plasma proteins</topic><topic>Protein Binding</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wasan, Ellen K</creatorcontrib><creatorcontrib>Waterhouse, Dawn</creatorcontrib><creatorcontrib>Sivak, Olena</creatorcontrib><creatorcontrib>Bally, Marcel B</creatorcontrib><creatorcontrib>Klasa, Richard J</creatorcontrib><creatorcontrib>Wasan, Kishor M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wasan, Ellen K</au><au>Waterhouse, Dawn</au><au>Sivak, Olena</au><au>Bally, Marcel B</au><au>Klasa, Richard J</au><au>Wasan, Kishor M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2002-07-08</date><risdate>2002</risdate><volume>241</volume><issue>1</issue><spage>57</spage><epage>64</epage><pages>57-64</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The objectives of this study were to determine the protein binding and lipoprotein distribution of G3139 and G3139 lipoplexes following incubation in human plasma, assess complement activation of, and the effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma on in vitro cellular uptake of G3139. Effect of concentration and time on incorporation of free and lipid associated (lipoplexes) [3H] Bcl-2 AO (25–600 ng/ml) into normolipidemic human plasma lipoproteins was determined by density gradient ultracentrifugation after incubation at 37 °C for 5, 30, 60 and 120 min. Protein binding in the lipoprotein deficient fractions (LPDP) was determined by equilibrium dialysis. Complement interaction was determined by ELISA after exposure of human plasma to AO+/− liposomes prepared in serial dilution. In vitro uptake of G3139 and G3139 lipoplexes into human melanoma cells was assessed qualitatively by fluorescence microscopy after 4-h exposure to G3139 (free or as lipoplexes) with or without pre-incubation of G3139 in normal human plasma. Analysis of Bcl-2 AO-lipoprotein interaction over time and concentration indicated no significant movement of the compound within the different lipoprotein and LPDP fractions. Majority of drug was recovered within LPDP fraction, and more than 85% of drug recovered within LPDP fraction was protein bound. No significant activation of complement was noted for either free AO or lipoplexes. Pre-incubation of free AO or AO-lipoplexes in human plasma resulted in a greater cellular uptake of AO-lipoplexes compared with plasma free controls. These findings suggest that the majority of [3H]Bcl-2 AO is plasma protein bound with little lipoprotein association and no significant movement between different lipoprotein and LPDP fractions. Plasma protein binding other than lipoprotein binding may be responsible for the difference in cellular uptake of free AO vs. cationic lipoplexes.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>12086721</pmid><doi>10.1016/S0378-5173(02)00131-X</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2002-07, Vol.241 (1), p.57-64
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_71856925
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Antineoplastic agents
Antisense therapy
Bcl-2
Biological and medical sciences
Blood Proteins - metabolism
Chemotherapy
Complement Activation - drug effects
Genes, bcl-2 - genetics
Genetic Therapy
Human complement proteins
Human melanoma cells
Humans
Lipids
Lipoplexes
Lipoproteins
Lipoproteins - metabolism
Medical sciences
Melanoma - drug therapy
Oligonucleotides, Antisense - pharmacology
Pharmacology. Drug treatments
Phosphorothioate oligodeoxynucleotides
Plasma proteins
Protein Binding
Tumor Cells, Cultured
title Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A17%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20protein%20binding,%20lipoprotein%20distribution%20and%20uptake%20of%20free%20and%20lipid-associated%20BCL-2%20antisense%20oligodeoxynucleotides%20(G3139)%20in%20human%20melanoma%20cells&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Wasan,%20Ellen%20K&rft.date=2002-07-08&rft.volume=241&rft.issue=1&rft.spage=57&rft.epage=64&rft.pages=57-64&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/S0378-5173(02)00131-X&rft_dat=%3Cproquest_cross%3E71856925%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71856925&rft_id=info:pmid/12086721&rft_els_id=S037851730200131X&rfr_iscdi=true